LSL Pharma Group Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Mar '26 Mar 9, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Market Capitalization	49	47	40	-	-	-	Upgrade
Market Cap Growth	14.85%	18.48%	-	-	-	-	Upgrade
Enterprise Value	71	61	54	-	-	-	Upgrade
Last Close Price	0.41	0.41	0.48	-	-	-	Upgrade
PE Ratio	17.85	14.28	-	-	-	-	Upgrade
PS Ratio	1.83	2.67	3.99	-	-	-	Upgrade
PB Ratio	1.93	1.90	4.62	-	-	-	Upgrade
P/TBV Ratio	4.44	4.13	-	-	-	-	Upgrade
EV/Sales Ratio	2.64	3.45	5.37	-	-	-	Upgrade
EV/EBITDA Ratio	17.63	35.92	-	-	-	-	Upgrade
EV/EBIT Ratio	49.96	150.86	-	-	-	-	Upgrade
Debt / Equity Ratio	0.85	0.87	1.88	2.84	1.15	1.02	Upgrade
Debt / EBITDA Ratio	5.39	11.30	-	-	47.86	4.08	Upgrade
Net Debt / Equity Ratio	0.85	0.86	1.88	2.84	1.08	0.84	Upgrade
Net Debt / EBITDA Ratio	5.68	12.52	-5.06	-2.52	117.34	3.44	Upgrade
Net Debt / FCF Ratio	-	-6.57	-2.10	-3.61	-6.00	-1.93	Upgrade
Asset Turnover	0.55	0.42	0.35	0.29	0.31	-	Upgrade
Inventory Turnover	-	1.88	2.37	2.92	2.19	-	Upgrade
Quick Ratio	-	0.54	0.18	0.09	0.29	0.35	Upgrade
Current Ratio	1.53	1.59	0.48	0.38	0.89	0.52	Upgrade
Return on Equity (ROE)	12.13%	19.78%	-121.50%	-98.29%	-16.56%	-	Upgrade
Return on Assets (ROA)	1.80%	0.60%	-8.84%	-14.99%	-1.57%	-	Upgrade
Return on Invested Capital (ROIC)	2.94%	1.12%	-18.20%	-31.11%	-3.36%	6.81%	Upgrade
Return on Capital Employed (ROCE)	3.00%	0.90%	-26.00%	-43.10%	-3.30%	11.50%	Upgrade
Earnings Yield	5.65%	7.00%	-21.19%	-	-	-	Upgrade
FCF Yield	-	-6.86%	-19.32%	-	-	-	Upgrade
Buyback Yield / Dilution	-19.11%	-31.18%	-20.94%	-11.78%	-8.34%	-14.88%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.